Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

IJIR publishes special/guest-edited issues and topical collections. The peer review process for articles included in topical collections/special issues is the same as the peer review process of the journal in general. Additionally, if the Guest Editors author an article in their topical collection/special issue, they will not handle the peer review process.​

Experience with intracavernous PGE-1 in the treatment of erectile dysfunction: dose considerations and efficacy


The recommended dose of PGE-1 as treatment for erectile dysfunction has ranged from 10–60 mcg in various studies. We conducted the present study to identify factors that influence dose tritration and maintenance. From 96 patients who presented to our institution with erectile impotence, 40 elected self injection with PGE-1. Erectile response to intracavernous injection was assessed in the course of office-based dose titration. Patients were stratified into different groups based on age and etiology of erectile dysfunction. The mean maintenance dose was calculated in each group. Patients were evaluated quarterly by physical palpation of the penis, complete blood count, serum electrolytes, and liver function tests in order to assess safety of therapy. The average maintenance dose varied with the etiology of erectile dysfunction and age of the patient. The central neurogenic group was the most responsive to PGE-1 therapy, requiring an average maintenace dosage of 5 mcg. Men with vascular etiologies required the largest maintenance dosage of 20 mcg. Furthermore, dosage requirement increased linearly with age. We conclude that dosing considerations vary widely in a clinical setting and their determination is greatly facilitated if primary and associated causes of erectile dysfunction and the age of the patient are considered.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ismail, M., Abbott, L. & Hirsch, I. Experience with intracavernous PGE-1 in the treatment of erectile dysfunction: dose considerations and efficacy. Int J Impot Res 9, 39–42 (1997).

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI:


  • prostaglandin E1
  • erectile dysfunction
  • intracavernous injection
  • dose considerations
  • efficacy
  • side effects

This article is cited by


Quick links